Find Liraglutide manufacturers, exporters & distributors on PharmaCompass

Rochem Liraglutide

Contact Supplier

Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

Contact Supplier

Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

xyz-pharma-m-2025-01-06

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

45 API Suppliers, 22 USDMF, 4 KDMF, 31 NDC API, 29 Listed Suppliers, $ API Reference Price

45 API Suppliers
22 USDMF
4 KDMF
31 NDC API
29 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

16 Drugs in Development

16 Drugs in Development

FINISHED DOSAGE FORMULATIONS

25 FDF Dossiers, 4 FDA Orange Book, 8 Europe, 3 Canada, 5 South Africa, 5 Listed Dossiers

25 FDF Dossiers
4 FDA Orange Book
8 Europe
3 Canada
5 South Africa
5 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 2 Actylis, 1 BASF, 1 Finar, 1 Kerry, 1 Pluviaendo, 1 Valens Pharmachem

relatedExcipients
1 Nanjing Well Pharmaceutical
2 Actylis
1 BASF
1 Finar
1 Kerry
1 Pluviaendo
1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 4 Topical, 3 Film Formers & Plasticizers, 2 Solubilizers, 1 Emulsifying Agents, 1 Controlled & Modified Release, 1 Thickeners and Stabilizers, 1 Coating Systems & Additives

excipientsByApplications
4 Parenteral
4 Topical
3 Film Formers & Plasticizers
2 Solubilizers
1 Emulsifying Agents
1 Controlled & Modified Release
1 Thickeners and Stabilizers
1 Coating Systems & Additives

DIGITAL CONTENT

6 DATA COMPILATION #PharmaFlow, 153 NEWS #PharmaBuzz

media
6 DATA COMPILATION #PharmaFlow
153 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

6 Finished Drug Prices, 23 Annual Reports

globalSalesInformation
6 Finished Drug Prices
23 Annual Reports

MARKET PLACE

17 APIs, 5 FDF Dossiers

marketPlace
17 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

41 US Patents, 6 Health Canada Patents

patents
41 US Patents
6 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

otherSolutions
1 Others

Rochem Liraglutide Popup

Synopsis

ACTIVE PHARMA INGREDIENTS

45

API Suppliers

22

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

0

EU WC

4

KDMF

31

NDC API

0

VMF

29

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 604,748

MARKET PLACE

17

API

5

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

25

FDF Dossiers

4

FDA Orange Book

FDA (Orange Book)

8

Europe

3

Canada

0

Australia

5

South Africa

5

Listed Dossiers

16DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

1

Others

PATENTS & EXCLUSIVITIES

41

US Patents

0

US Exclusivities

6

Health Canada Patents

DIGITAL CONTENT

6

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

153

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

NA

Annual Reports (USD Million)

33,460

Finished Drug Prices

8 RELATED EXCIPIENT COMPANIES

17EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: Victoza, 204656-20-2, Liraglutida, Liraglutidum, Nn2211, Nn-2211

Molecular Formula

C₁₇₂H₂₆₅N₄₃O₅₁

Molecular Weight

3751 g/mol

InChI Key

YSDQQAXHVYUZIW-QCIJIYAXSA-N

Liraglutide

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

1 2D Structure

Liraglutide

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid

2.1.2 InChI

InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1

2.1.3 InChI Key

YSDQQAXHVYUZIW-QCIJIYAXSA-N

2.1.4 Canonical SMILES

CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O

2.1.5 Isomeric SMILES

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. 2211, Nn

2. Nn 2211

3. Nn-2211

4. Nn2211

5. Saxenda

6. Victoza

2.2.2 Depositor-Supplied Synonyms

1. Victoza

2. 204656-20-2

3. Liraglutida

4. Liraglutidum

5. Nn2211

6. Nn-2211

7. Nn 2211

8. Chembl4084119

9. Saxenda

10. Liraglutidum [inn-latin]

11. Liraglutida [inn-spanish]

12. Unii-839i73s42a

13. Hsdb 8205

14. Liraglutide [usan:inn:ban:jan]

15. Gtpl1133

16. Chebi:71193

17. Dtxsid60174433

18. Ex-a2418

19. Bdbm50240819

20. Akos037435224

21. N26-(hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

22. 839i73s42a

23. N26-(hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide

24. As-56276

25. A16115

26. Arg34lys26-(n-epsilon-(gamma-glu(n-alpha-hexadecanoyl)))-glp-1(7-37)

27. N(sup 26)-(hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

2.3 Create Date

2007-07-04

3 Chemical and Physical Properties

Molecular Formula	C₁₇₂H₂₆₅N₄₃O₅₁
Molecular Weight	3751 g/mol
XLogP3	-3.4
Hydrogen Bond Donor Count	54
Hydrogen Bond Acceptor Count	55
Rotatable Bond Count	132
Exact Mass	3749.9498161 g/mol
Monoisotopic Mass	3748.9464612 g/mol
Topological Polar Surface Area	1510 Å²
Heavy Atom Count	266
Formal Charge	0
Complexity	8760
Isotope Atom Count	0
Defined Atom Stereocenter Count	31
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Victoza
PubMed Health	Liraglutide (Injection)
Drug Classes	Antidiabetic
Drug Label	Victoza contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to b...
Active Ingredient	Liraglutide recombinant
Dosage Form	Solution
Route	Subcutaneous
Strength	18mg/3ml (6mg/ml)
Market Status	Prescription
Company	Novo Nordisk

2 of 2
Drug Name	Victoza
PubMed Health	Liraglutide (Injection)
Drug Classes	Antidiabetic
Drug Label	Victoza contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to b...
Active Ingredient	Liraglutide recombinant
Dosage Form	Solution
Route	Subcutaneous
Strength	18mg/3ml (6mg/ml)
Market Status	Prescription
Company	Novo Nordisk

4.2 Therapeutic Uses

Hypoglycemic Agents

National Library of Medicine's Medical Subject Headings. Liraglutide. Online file (MeSH, 2014). Available from, as of April 30 2014: https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html

Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. /Included in US product label/

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

Because of the uncertain relevance of the rodent thyroid C-cell tumor findings to humans, prescribe Victoza only to patients for whom the potential benefits are considered to outweigh the potential risk. Victoza is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. ... Victoza is not a substitute for insulin. Victoza should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

EXPL THER: According to World Health Organization estimates, type 2 diabetes (T2D) is an epidemic (particularly in under developed countries) and a socio-economic challenge. This is even more relevant since increasing evidence points to T2D as a risk factor for Alzheimer's disease (AD), supporting the hypothesis that AD is a "type 3 diabetes" or "brain insulin resistant state". Despite the limited knowledge on the molecular mechanisms and the etiological complexity of both pathologies, evidence suggests that neurodegeneration/death underlying cognitive dysfunction (and ultimately dementia) upon long-term T2D may arise from a complex interplay between T2D and brain aging. Additionally, decreased brain insulin levels/signaling and glucose metabolism in both pathologies further suggests that an effective treatment strategy for one disorder may be also beneficial in the other. In this regard, one such promising strategy is a novel successful anti-T2D class of drugs, the glucagon-like peptide-1 (GLP-1) mimetics (e.g. exendin-4 or liraglutide), whose potential neuroprotective effects have been increasingly shown in the last years. In fact, several studies showed that, besides improving peripheral (and probably brain) insulin signaling, GLP-1 analogs minimize cell loss and possibly rescue cognitive decline in models of AD, Parkinson's (PD) or Huntington's disease. Interestingly, exendin-4 is undergoing clinical trials to test its potential as an anti-PD therapy. Herewith, we aim to integrate the available data on the metabolic and neuroprotective effects of GLP-1 mimetics in the central nervous system (CNS) with the complex crosstalk between T2D-AD, as well as their potential therapeutic value against T2D-associated cognitive dysfunction. C

PMID:23314196 Duarte AI et al; Biochim Biophys Acta 1832 (4): 527-41 (2013)

4.3 Drug Warning

/BOXED WARNING/ WARNING: RISK OF THYROID C-CELL TUMORS. Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Victoza is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Based on the findings in rodents, monitoring with serum calcitonin or thyroid ultrasound was performed during clinical trials, but this may have increased the number of unnecessary thyroid surgeries. It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumors. Patients should be counseled regarding the risk and symptoms of thyroid tumors.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with Victoza. If a hypersensitivity reaction occurs, the patient should discontinue Victoza and other suspect medications and promptly seek medical advice.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with Victoza. After initiation of Victoza, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, Victoza should promptly be discontinued and appropriate management should be initiated. If pancreatitis is confirmed, Victoza should not be restarted. Consider antidiabetic therapies other than Victoza in patients with a history of pancreatitis.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

In postmarketing reports, acute renal failure and worsening of chronic renal failure (which may require hemodialysis) have been reported with liraglutide. Some of these events occurred in patients without known underlying renal disease. Most of these events occurred in patients experiencing nausea, vomiting, diarrhea, or dehydration. Some of these events occurred in patients receiving liraglutide in combination with one or more agents known to affect renal function or hydration status. Liraglutide has not been found to be directly nephrotoxic in preclinical or clinical studies. Renal effects usually have been reversible with supportive treatment and discontinuance of potentially causative agents, including liraglutide. Clinicians should use caution when initiating liraglutide or escalating dosage in patients with renal impairment.

American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014, p. 3217

For more Drug Warnings (Complete) data for Liraglutide (15 total), please visit the HSDB record page.

4.4 Drug Indication

Liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular disease.

FDA Label

Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of

30 kg/m (obese), or

27 kg/m to < 30 kg/m (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Treatment with Saxenda should be discontinued after 12 weeks on the 3. 0 mg/day dose if patients have not lost at least 5% of their initial body weight.

Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications

- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.

Treatment of type II diabetes mellitus

Treatment of obesity

5 Pharmacology and Biochemistry

5.1 Pharmacology

Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous tissue and bloodstream and be released slowly over time. Binding with albumin results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-1. The effect of liraglutide is the increased secretion of insulin and decreased secretion of glucagon in response to glucose as well as slower gastric emptying. Liraglutide also does not adversely affect glucagon secretion in response to low blood sugar.

5.2 MeSH Pharmacological Classification

Hypoglycemic Agents

Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)

Incretins

Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially. (See all compounds classified as Incretins.)

5.3 FDA Pharmacological Classification

5.3.1 Pharmacological Classes

Glucagon-Like Peptide 1 [CS]; Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]; GLP-1 Receptor Agonist [EPC]

5.4 ATC Code

A10BJ02

A10BJ02

A - Alimentary tract and metabolism

A10 - Drugs used in diabetes

A10B - Blood glucose lowering drugs, excl. insulins

A10BJ - Glucagon-like peptide-1 (glp-1) analogues

A10BJ02 - Liraglutide

5.5 Absorption, Distribution and Excretion

Absorption

Bioavailability of liraglutide after subcutaneous injection is approximately 55% and maximum concentrations are reached after 11.7 hours.

Route of Elimination

6% excreted in urine and 5% excreted in feces.

Volume of Distribution

13L.

Clearance

1.2L/h.

The mean apparent volume of distribution after subcutaneous administration of Victoza 0.6 mg is approximately 13 L. The mean volume of distribution after intravenous administration of Victoza is 0.07 L/kg. Liraglutide is extensively bound to plasma protein (>98%).

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

Following a 3(H)-liraglutide dose, intact liraglutide was not detected in urine or feces. Only a minor part of the administered radioactivity was excreted as liraglutide-related metabolites in urine or feces (6% and 5%, respectively). The majority of urine and feces radioactivity was excreted during the first 6-8 days. The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/hr with an elimination half-life of approximately 13 hours, making Victoza suitable for once daily administration.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

Following subcutaneous administration, maximum concentrations of liraglutide are achieved at 8-12 hours post dosing. The mean peak (Cmax) and total (AUC) exposures of liraglutide were 35 ng/mL and 960 ng hr/mL, respectively, for a subcutaneous single dose of 0.6 mg. After subcutaneous single dose administrations, Cmax and AUC of liraglutide increased proportionally over the therapeutic dose range of 0.6 mg to 1.8 mg. At 1.8 mg Victoza, the average steady state concentration of liraglutide over 24 hours was approximately 128 ng/mL. AUC0-8 was equivalent between upper arm and abdomen, and between upper arm and thigh. AUC0-8 from thigh was 22% lower than that from abdomen. However, liraglutide exposures were considered comparable among these three subcutaneous injection sites. Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

Liraglutide is a novel once-daily human glucagon-like peptide (GLP)-1 analog in clinical use for the treatment of type 2 diabetes. To study metabolism and excretion of 3(H)-liraglutide, a single subcutaneous dose of 0.75 mg/14.2 MBq was given to healthy males. The recovered radioactivity in blood, urine, and feces was measured, and metabolites were profiled. In addition, 3(H)-liraglutide and [(3)H]GLP-1(7-37) were incubated in vitro with dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase (NEP) to compare the metabolite profiles and characterize the degradation products of liraglutide. The exposure of radioactivity in plasma (area under the concentration-time curve from 2 to 24 hr) was represented by liraglutide (> or = 89%) and two minor metabolites (totaling < or =11%). Similarly to GLP-1, liraglutide was cleaved in vitro by DPP-IV in the Ala8-Glu9 position of the N terminus and degraded by NEP into several metabolites. The chromatographic retention time of DPP-IV-truncated liraglutide correlated well with the primary human plasma metabolite [GLP-1(9-37)], and some of the NEP degradation products eluted very close to both plasma metabolites. Three minor metabolites totaling 6 and 5% of the administered radioactivity were excreted in urine and feces, respectively, but no liraglutide was detected. In conclusion, liraglutide is metabolized in vitro by DPP-IV and NEP in a manner similar to that of native GLP-1, although at a much slower rate. The metabolite profiles suggest that both DPP-IV and NEP are also involved in the in vivo degradation of liraglutide. The lack of intact liraglutide excreted in urine and feces and the low levels of metabolites in plasma indicate that liraglutide is completely degraded within the body.

PMID:20709939 Malm-Erjefalt M et al; Drug Metab Dispos 38 (11): 1944-53 (2010)

For more Absorption, Distribution and Excretion (Complete) data for Liraglutide (8 total), please visit the HSDB record page.

5.6 Metabolism/Metabolites

Liraglutide is less sensitive to metabolism than the endogenous GLP-1 and so is more slowly metabolized by dipeptidyl peptidase-4 and neutral endopeptidase to various smaller polypeptides which have not all been structurally determined. A portion of Liraglutide may be completely metabolized to carbon dioxide and water.

The metabolic and excretion patterns were highly similar across species with liraglutide being fully metabolised in the body by sequential cleavage of small peptide fragments and amino acids. The in vitro metabolism studies indicate that the initial metabolism involves cleavage of the peptide backbone with no degradation of the glutamate-palmitic acid side-chain. Mice, rats and monkeys displayed similar plasma profiles and showed no significant gender differences. A higher number of metabolites were observed in plasma from the animal species (especially the rat and monkey) as compared to human plasma. This disparity can partly be explained by differences in the sample preparation as human plasma samples were freeze dried prior to analysis causing a removal of volatile metabolites (including tritiated water). All detected metabolites were minor and obtained in low amount (<15%) and therefore no structural identification of these was performed. This is acceptable since the metabolites are only formed in low amounts and since the metabolites are expected to resemble endogenous substances with well-known metabolic pathways

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Victoza (Liraglutide) p.10 (2009). Available from, as of July 16, 2014: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf

During the initial 24 hours following administration of a single 3(H)-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide. Liraglutide is endogenously metabolized /SRP: in a manner similar to large proteins/ without a specific organ as a major route of elimination.

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

5.7 Biological Half-Life

Terminal half life of 13 hours.

The terminal half-life of liraglutide seems to be similar in pigs (approximately 14 hr) and humans (approximately 15 hr) while shorter in mice, rats, rabbits and monkeys (4-8 hr). Several studies in monkeys, pigs and humans indicated that extravascular administration (SC and pulmonary) of liraglutide prolongs the terminal half-life as compared to intravenous (IV) administration. Furthermore, the terminal half-life seemed also to be prolonged by repeated dosing in rats, monkeys, pigs and humans. This tendency was not apparent for mice and rabbits.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Victoza (Liraglutide) p.9 (2009). Available from, as of July 16, 2014: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf

elimination half-life ... approximately 13 hours

NIH; DailyMed. Current Medication Information for Victoza (Liraglutide (rDNA Origin) Injection) Injection, Solution (Revised: April 2013). Available from, as of July 15, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

5.8 Mechanism of Action

Liraglutide is an acylated synthetic glucagon-like peptide-1 analog. Liraglutide is an agonist of the glucagon-like peptide-1 receptor which is coupled to adenylate cyclase. The increase in cyclic AMP stimulates the glucose dependant release of insulin, inhibits the glucose dependant release of glucagon, and slows gastric emptying to increase control of blood sugar.

Liraglutide is an acylated, long-acting, human glucagon-like peptide-1 (GLP-1) receptor agonist; the synthetic (recombinant DNA origin) peptide precursor of liraglutide has 97% amino acid sequence homology to endogenous human GLP-1-(7-37). Liraglutide is prepared by attaching palmitic acid with a glutamic acid spacer on the lysine residue at position 26 of the peptide precursor. GLP-1-(7-37) represents less than 20% of total circulating endogenous GLP-1. Like GLP-1-(7-37), liraglutide activates the GLP-1 receptor in pancreatic beta cells. Liraglutide also increases intracellular cyclic 3',5'-adenosine monophosphate (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. In addition, liraglutide suppresses glucagon secretion in a glucose-dependent manner but does not impair normal glucagon response to hypoglycemia. Liraglutide delays gastric emptying, reducing the rate at which postprandial glucose appears in the circulation. As a result of these actions resulting in increased insulin secretion, suppression of glucagon secretion, and delays in gastric emptying, liraglutide effectively reduces fasting and postprandial plasma glucose concentrations in patients with type 2 diabetes mellitus.

American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014, p. 3217-8

Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical trials have suggested that treatment with GLP-1 mimetics may also diminish the risk of cardiovascular disease in diabetic patients. The mechanism responsible for this effect has yet to be determined; however, one possibility is that they might do so by a direct effect on vascular endothelium. Since low grade inflammation of the endothelium is an early event in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined the effects of liraglutide on inflammation in cultured human aortic endothelial cells (HAECs). Liraglutide reduced the inflammatory responses to TNFalpha and LPS stimulation, as evidenced by both reduced protein expression of the adhesion molecules VCAM-1 and E-Selectin, and THP-1 monocyte adhesion. This was found to result from increased cell Ca2+ and several molecules sensitive to Ca2+ with known anti inflammatory actions in endothelial cells, including CaMKKbeta, CaMKI, AMPK, eNOS and CREB. Treatment of the cells with STO-609, a CaMKK inhibitor, diminished both the activation of AMPK, CaMKI and the inhibition of TNFa and LPS-induced monocyte adhesion by liraglutide. Likewise, expression of an shRNA against AMPK nullified the anti-inflammatory effects of liraglutide. The results indicate that liraglutide exerts a strong anti-inflammatory effect on HAECs. They also demonstrate that this is due to its ability to increase intracellular Ca2+ and activate CAMKKbeta, which in turn activates AMPK.

PMID:2483525 Krasner NM et al; PLoS One. 2014 May 16;9(5):e97554. doi: 10.1371/journal.pone.0097554. eCollection 2014.

In vivo, liraglutide lowers blood glucose and body weight in a number of diabetic and obese models using rodents, pigs and monkeys. The mechanism of action in vivo involved glucose-dependent increase in insulin secretion, lowered glucagon secretion, decreased gastric emptying, loss of body fat, lowered food intake, altered food preference, and maintained energy expenditure. The mechanism of action is consistent with a specific GLP-1 effect.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Victoza (Liraglutide) p.9 (2009). Available from, as of July 16, 2014: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf

Liraglutide is a long-acting GLP-1 analogue, designed to bind to albumin as the main molecular mechanism of protraction. In vitro, this was shown in the receptor cAMP as well as binding assay where addition of albumin right-shifted the dose-response and/or binding curve. The apparent reduced potency of liraglutide underlines that only the free fraction of liraglutide is responsible for its pharmacological effect in vitro as well as in vivo. Furthermore, liraglutide in a pharmaceutical solution forms a micell-like heptamer which may contribute to the slow absorption from the subcutis.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Victoza (Liraglutide) p.8 (2009). Available from, as of July 16, 2014: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf

API SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Bachem Americas Inc

Switzerland

Biotech Showcase

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Contact Supplier

Contact Supplier

Switzerland

Digital Content

LIRAGLUTIDE

GDUFA

DMF Review : Complete

Rev. Date : 2020-11-05

Pay. Date : 2020-08-20

DMF Number : 33366

Submission : 2020-08-31

Status : Active

Type : II

Bachem company banner

Product Web Link

Digital Content

02

Bachem Ag

Switzerland

Biotech Showcase

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Contact Supplier

Contact Supplier

Switzerland

Digital Content

LIRAGLUTIDE DRUG SUBSTANCE

GDUFA

DMF Review : Complete

Rev. Date : 2016-10-07

Pay. Date : 2016-05-11

DMF Number : 30467

Submission : 2016-06-29

Status : Active

Type : II

Bachem company banner

Product Web Link

Digital Content

03

Alp Pharm Beijing Co Ltd

China

BIO Partnering at JPM

Not Confirmed

04

Ambiopharm Inc

U.S.A

BIO Partnering at JPM

Not Confirmed

05

Amphastar Nanjing Pharmaceuticals In...

U.S.A

BIO Partnering at JPM

Not Confirmed

06

Chengdu Shengnuo Biopharm Co Ltd

China

BIO Partnering at JPM

Not Confirmed

07

Chengdu Shengnuo Biopharm Co Ltd

China

BIO Partnering at JPM

Not Confirmed

08

Hybio Pharmaceutical Co Ltd

China

BIO Partnering at JPM

Not Confirmed

09

Shenzhen Jymed Technology Co Ltd

China

BIO Partnering at JPM

Not Confirmed

10

Sinopep-allsino Biopharmaceutical Co...

China

BIO Partnering at JPM

Not Confirmed

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

01

Biocon

India

BIO Partnering at JPM

Not Confirmed

02

Sinopep Pharmaceutical Inc

China

BIO Partnering at JPM

Not Confirmed

03

Zhejiang Peptites Biotech Co.,Ltd

China

BIO Partnering at JPM

Not Confirmed

04

BIO Partnering at JPM

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

01

Dr. Reddy's Laboratories Limited

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

India

Digital Content

LIRAGLUTIDE

NDC Package Code : 71796-022

Start Marketing Date : 2020-06-30

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Dr Reddy Company Banner

Product Web Link

Digital Content

02

Shanghai Ambiopharm, Inc

U.S.A

Biotech Showcase

Not Confirmed

03

Nanjing Hanxin Pharmaceutical Techn...

China

Biotech Showcase

Not Confirmed

04

Hybio Pharmaceutical Co., Ltd. (Pin...

China

Biotech Showcase

Not Confirmed

05

Hybio Pharmaceutical Co., Ltd. (Pin...

China

Biotech Showcase

Not Confirmed

06

Hybio Pharmaceutical Co., Ltd. (Pin...

China

Biotech Showcase

Not Confirmed

07

Nanjing Xingyin Pharmaceutical Grou...

China

Biotech Showcase

Not Confirmed

08

ScinoPharm Taiwan Ltd.

Taiwan

Biotech Showcase

Not Confirmed

09

Zhejiang Peptites Biotech Co., Ltd.

China

Biotech Showcase

Not Confirmed

10

Hangzhou Sinodo Pharm Technology Co...

Country

Biotech Showcase

Not Confirmed

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Rochem International Inc

U.S.A

Suppliers Night Expo

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

Contact Supplier

U.S.A

Digital Content

Liraglutide

About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.

Product Web Link

Digital Content

02

ChemWerth Inc

U.S.A

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

Contact Supplier

U.S.A

Digital Content

Liraglutide

About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...

Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs to regulated markets worldwide and has exclusive partnerships for new product development, compliance support and secure supply chain logistics. ChemWerth has access to over 500 APIs and more than 30 manufacturing facilities in the US, Europe, India and China. ChemWerth acts as a regulatory agent for over 25 FDA-approved facilities and sells more than 100 products. It has established its presence in 38 countries. In 2020, ChemWerth filed its 500th DMF with the FDA.

Chemwerth Compnay Banner

Product Web Link

Digital Content

03

Transo-Pharm USA LLC

U.S.A

Biotech Showcase

Not Confirmed

TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Contact Supplier

Contact Supplier

U.S.A

Digital Content

Liraglutide

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.

Transo Pharm USA Company Banner

Product Web Link

Digital Content

04

LGM Pharma

U.S.A

Biotech Showcase

Not Confirmed

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Contact Supplier

U.S.A

Digital Content

Liraglutide

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.

Product Web Link

Digital Content

05

Bachem AG

Switzerland

Biotech Showcase

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Contact Supplier

Contact Supplier

Switzerland

Digital Content

Liraglutide

About the Company : With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology comp...

With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide, providing a wide range of services. Over the years, Bachem has established itself as a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company is headquartered in Switzerland and has offices in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Bachem company banner

Product Web Link

Digital Content

06

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

India

Digital Content

Liraglutide

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale

Dr Reddy Company Banner

Product Web Link

Digital Content

07

HRV Global Life Sciences

India

Biotech Showcase

Not Confirmed

HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Contact Supplier

Contact Supplier

India

Digital Content

Liraglutide

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.

HRV Global Life Sciences

Product Web Link

Digital Content

08

Supriya Lifescience

India

Biotech Showcase

Not Confirmed

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Contact Supplier

Contact Supplier

India

Digital Content

Liraglutide

About the Company : Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Su...

Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Supriya follows industry standards and constantly improves to deliver quality products. Its facility is 47,000 square meters with dedicated areas for warehouse, QA, QC, R&D, production and finished products. The current capacity is 550 KL, with plans to expand to over 1000 KL by 2024. Supriya has 14 active USDMFs, 8 active CEPs, strong R&D and compliant facilities worldwide. Supriya works with innovators, generic companies, and as a CMO.

Product Web Link

Digital Content

09

USV Private Limited

India

Biotech Showcase

Not Confirmed

USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.

Contact Supplier

Contact Supplier

India

Digital Content

Liraglutide

About the Company : USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Union and Japan), Brande...

USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Union and Japan), Branded Generics and Bio-therapeutics. USV also specializes in Research and Development in Biotechnology, Drug Delivery and Chemistry.31 APIs are currently on offer, 13 are in advanced stages of development and 14 are under development. Segments covered include Diabetes, Cardiology, CNS, Oncology, Dermatology and Ophthalmology.

USV Private Limited

Portfolio PDF

Product Web Link

Digital Content

10

Omgene Life Sciences Pvt. Ltd

India

Biotech Showcase

Not Confirmed

Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Contact Supplier

Contact Supplier

India

Digital Content

Liraglutide

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.

Omgene Company Banner

Product Web Link

Digital Content

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q1","strtotime":1612549800,"product":"LIRAGLUTIDE","address":"1ST FLOOR,PLOT NO.497,VIVEKANANDANAGAR COLONY, KUKATPALLY","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"ICURE BNP","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.00","actualQuantity":"0.002","unit":"KGS","unitRateFc":"2717385.7","totalValueFC":"5378.3","currency":"USD","unitRateINR":195787640,"date":"06-Feb-2021","totalValueINR":"391575.28","totalValueInUsd":"5378.3","indian_port":"HYDERABAD AIR","hs_no":"29141990","bill_no":"8456253","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"1ST FLOOR,PLOT NO.497,VIVEKANANDANAGAR COLONY, KUKATPALLY, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q1","strtotime":1615487400,"product":"LIRAGLUTIDE R&D SAMPLE","address":"PLOT NO.8, ALEAP INDUSTRIAL ESTATE ,,NEAR PRAGATHI NAGAR, KUKATPALLY,","city":"HYDERABAD,TELANGANA","supplier":"SAJJALA BIO LABS","supplierCountry":"INDIA","foreign_port":"MADRID","customer":"EMPRESA","customerCountry":"SPAIN","quantity":"0.00","actualQuantity":"1.74","unit":"GMS","unitRateFc":"1002.1","totalValueFC":"1725.6","currency":"USD","unitRateINR":72200,"date":"12-Mar-2021","totalValueINR":"125628","totalValueInUsd":"1725.6","indian_port":"HYDERABAD AIR","hs_no":"29371900","bill_no":"9295738","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.8, ALEAP INDUSTRIAL ESTATE ,,NEAR PRAGATHI NAGAR, KUKATPALLY,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q2","strtotime":1620671400,"product":"LIRAGLUTIDE (R&D SAMPLE)","address":"PLOT NO.8, ALEAP INDUSTRIAL ESTATE ,,NEAR PRAGATHI NAGAR, KUKATPALLY,","city":"HYDERABAD,TELANGANA","supplier":"SAJJALA BIO LABS","supplierCountry":"INDIA","foreign_port":"MADRID","customer":"EMPRESA","customerCountry":"SPAIN","quantity":"0.02","actualQuantity":"15","unit":"GMS","unitRateFc":"1013.9","totalValueFC":"14959.2","currency":"USD","unitRateINR":73050,"date":"11-May-2021","totalValueINR":"1095750","totalValueInUsd":"14959.2","indian_port":"HYDERABAD AIR","hs_no":"29371900","bill_no":"1697155","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.8, ALEAP INDUSTRIAL ESTATE ,,NEAR PRAGATHI NAGAR, KUKATPALLY,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q2","strtotime":1621535400,"product":"LIRAGLUTIDE (SEC-69, IMPORT GOODS RE-EXP","address":"307, 3RD FLOOR, STUDIO COMPLEX NR. GOTA CROSS ROAD SG HIGHWAY","city":"AHMEDABAD","supplier":"K KYEMISTRY INDIA ","supplierCountry":"INDIA","foreign_port":"SINGAPORE","customer":"MERIDIAN INDUSTRIES (ASIA PACIFIC)","customerCountry":"SINGAPORE","quantity":"0.78","actualQuantity":"776","unit":"GMS","unitRateFc":"825","totalValueFC":"632210.5","currency":"USD","unitRateINR":59676.546391752578,"date":"21-May-2021","totalValueINR":"46309000","totalValueInUsd":"632210.5","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"1918581","productDescription":"Re-export","marketType":"LESS REGULATED MARKET","country":"SINGAPORE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"307, 3RD FLOOR, STUDIO COMPLEX NR. GOTA CROSS ROAD SG HIGHWAY, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1654626600,"product":"LIRAGLUTIDE( R-DNA ORIGIN)","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA","customer":"VIATRIS","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"234","totalValueFC":"460.7","currency":"USD","unitRateINR":17971,"date":"08-Jun-2022","totalValueINR":"35942","totalValueInUsd":"460.7","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4002752","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659897000,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,,ELECTRONIC C","city":"BANGALORE,KARNATAKA","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"GALENICUM","customerCountry":"SPAIN","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"725.1","totalValueFC":"14251.8","currency":"USD","unitRateINR":56698.949999999997,"date":"08-Aug-2022","totalValueINR":"1133979","totalValueInUsd":"14251.8","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4003941","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,,ELECTRONIC C, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675621800,"product":"LIRAGLUTIDE(QTY:1.399 KGS)","address":"2ND FLOOR, PLOT NO.2, MAITHRIVIHAR, AMEERPET,","city":"HYDERABAD, AP.","supplier":"AURO PEPTIDES LIMITED","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"EUGIA US MANUFACTURING LLC","customerCountry":"UNITED STATES","quantity":"1.40","actualQuantity":"1.399","unit":"KGS","unitRateFc":"750000","totalValueFC":"1028719.9","currency":"USD","unitRateINR":60730521.80128663,"date":"06-Feb-2023","totalValueINR":"84962000","totalValueInUsd":"1028719.9","indian_port":"HYDERABAD AIR","hs_no":"29371900","bill_no":"7560210","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"2ND FLOOR, PLOT NO.2, MAITHRIVIHAR, AMEERPET,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679596200,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"GALENICUM","customerCountry":"SPAIN","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"5253","totalValueFC":"5233.8","currency":"USD","unitRateINR":430483,"date":"24-Mar-2023","totalValueINR":"430483","totalValueInUsd":"5233.8","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4001629","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691692200,"product":"(D-ASP9)-LIRAGLUTIDE","address":"#N\/A","city":"#N\/A","supplier":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"NA","customer":"CIPLA","customerCountry":"BRAZIL","quantity":"0.02","actualQuantity":"0.017","unit":"KGS","unitRateFc":"260719.7","totalValueFC":"4382.1","currency":"USD","unitRateINR":21352939.094117645,"date":"11-Aug-2023","totalValueINR":"362999.9646","totalValueInUsd":"4382.1","indian_port":"HYDERABAD ICD","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"#N\/A, #N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691692200,"product":"B-ASP9-LIRAGLUTIDE","address":"#N\/A","city":"#N\/A","supplier":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"NA","customer":"CIPLA","customerCountry":"BRAZIL","quantity":"0.02","actualQuantity":"0.016","unit":"KGS","unitRateFc":"199939","totalValueFC":"3162.9","currency":"USD","unitRateINR":16374998.981250001,"date":"11-Aug-2023","totalValueINR":"261999.9837","totalValueInUsd":"3162.9","indian_port":"HYDERABAD ICD","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"#N\/A, #N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691692200,"product":"FRAGMENT-(3-31)-LIRAGLUTIDE","address":"#N\/A","city":"#N\/A","supplier":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"NA","customer":"CIPLA","customerCountry":"BRAZIL","quantity":"0.02","actualQuantity":"0.016","unit":"KGS","unitRateFc":"277014.7","totalValueFC":"4382.1","currency":"USD","unitRateINR":22687497.787500001,"date":"11-Aug-2023","totalValueINR":"362999.9646","totalValueInUsd":"4382.1","indian_port":"HYDERABAD ICD","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"#N\/A, #N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691692200,"product":"FRAGMENT-(4-31)-LIRAGLUTIDE","address":"#N\/A","city":"#N\/A","supplier":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"NA","customer":"CIPLA","customerCountry":"BRAZIL","quantity":"0.02","actualQuantity":"0.016","unit":"KGS","unitRateFc":"199939","totalValueFC":"3162.9","currency":"USD","unitRateINR":16374998.981250001,"date":"11-Aug-2023","totalValueINR":"261999.9837","totalValueInUsd":"3162.9","indian_port":"HYDERABAD ICD","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"#N\/A, #N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693161000,"product":"LIRAGLUTIDE DRUG SUBSTANCE BATCH NO:BM23","address":"20TH K M HOSUR ROADELECTRONIC C ITY P.O","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"Z TO ORDER AND NA","customerCountry":"SPAIN","quantity":"0.00","actualQuantity":"3.52","unit":"GMS","unitRateFc":"1477.3","totalValueFC":"5421.5","currency":"EUR","unitRateINR":127585.14204545454,"date":"28-Aug-2023","totalValueINR":"449099.7","totalValueInUsd":"5421.5","indian_port":"BANGALORE AIR","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"20TH K M HOSUR ROADELECTRONIC C ITY P.O, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1696012200,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"MADRID","customer":"GALENICUM","customerCountry":"SPAIN","quantity":"0.01","actualQuantity":"6","unit":"GMS","unitRateFc":"3577.4","totalValueFC":"21281.1","currency":"USD","unitRateINR":294417.16666666669,"date":"30-Sep-2023","totalValueINR":"1766503","totalValueInUsd":"21281.1","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4005228","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700159400,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.03","actualQuantity":"30","unit":"GMS","unitRateFc":"656.6","totalValueFC":"19478.6","currency":"USD","unitRateINR":54066.666666666664,"date":"17-Nov-2023","totalValueINR":"1622000","totalValueInUsd":"19478.6","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4006045","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704738600,"product":"LIRAGLUTIDE","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"ASUNCION","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"SWITZERLAND","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"1842750","totalValueFC":"35721.2","currency":"USD","unitRateINR":148442415,"date":"09-Jan-2024","totalValueINR":"2968848.3","totalValueInUsd":"35721.2","indian_port":"Hyderabad Air","hs_no":"29371200","bill_no":"6630394","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708021800,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"GALENICUM","customerCountry":"SPAIN","quantity":"0.00","actualQuantity":"3","unit":"GMS","unitRateFc":"1560.4","totalValueFC":"4637.4","currency":"USD","unitRateINR":128260.66666666667,"date":"16-Feb-2024","totalValueINR":"384782","totalValueInUsd":"4637.4","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4000828","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709490600,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"GALENICUM","customerCountry":"SPAIN","quantity":"0.09","actualQuantity":"86","unit":"GMS","unitRateFc":"616.1","totalValueFC":"52452.5","currency":"USD","unitRateINR":50644.616279069771,"date":"04-Mar-2024","totalValueINR":"4355437","totalValueInUsd":"52452.5","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4001132","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1718821800,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,","city":"BANGALORE","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"LISBOA","customer":"XXTAVXXSO XXADIXX SOXXTIOXX LDX","customerCountry":"PORTUGAL","quantity":"0.49","actualQuantity":"494","unit":"GMS","unitRateFc":"356.8","totalValueFC":"174386.5","currency":"USD","unitRateINR":29469,"date":"20-Jun-2024","totalValueINR":"14557686","totalValueInUsd":"174386.5","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4003066","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727634600,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,,ELECTRONIC C","city":"BANGALORE,KARNATAKA","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"MUSCAT","customer":"HAYAT BIOCARE SPC","customerCountry":"OMAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"340000","totalValueFC":"1856178.2","currency":"EUR","unitRateINR":31110000,"date":"30-Sep-2024","totalValueINR":"155550000","totalValueInUsd":"1856178.2","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4484336","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,,ELECTRONIC C, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727634600,"product":"LIRAGLUTIDE","address":"20TH K M, HOSUR ROAD,,ELECTRONIC C","city":"BANGALORE,KARNATAKA","supplier":"BIOCON","supplierCountry":"INDIA","foreign_port":"N\/A","customer":"HAYAT BIOCARE SPC","customerCountry":"OMAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"375271.4","totalValueFC":"1856178.2","currency":"USD","unitRateINR":31110000,"date":"30-Sep-2024","totalValueINR":"155550000","totalValueInUsd":"1856178.2","indian_port":"Biocon-SEZ","hs_no":"29371900","bill_no":"4484085","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"20TH K M, HOSUR ROAD,,ELECTRONIC C, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q1","strtotime":1610562600,"product":"LIRAGLUTIDE","address":"159, C.S.T. ROAD,KALINA, SANTACRUZ (E)","city":"MUMBAI,MAHARASHTRA","supplier":"HYBIO PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"GUANGZHOU","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"3","unit":"GMS","unitRateFc":"1800","totalValueFC":"5604.6","currency":"USD","unitRateINR":"136634.8","date":"14-Jan-2021","totalValueINR":"409904.28","totalValueInUsd":"5604.6","indian_port":"BOMBAY AIR","hs_no":"29371900","bill_no":"2351110","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"GUANGZHOU","supplierAddress":"","customerAddress":"159, C.S.T. ROAD,KALINA, SANTACRUZ (E)"},{"dataSource":"API Import","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q1","strtotime":1613068200,"product":"LIRAGLUTIDE-RESIN (LAB CHEMICALS) (50 GMS","address":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD","city":"VADODARA","supplier":"NANJING XINBELL PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"ALEMBIC PHARMACEUTICALS LIMITED","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"240000","totalValueFC":"12163.7","currency":"USD","unitRateINR":"17712000","date":"12-Feb-2021","totalValueINR":"885600","totalValueInUsd":"12163.7","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2735090","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"","customerAddress":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD"},{"dataSource":"API Import","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q1","strtotime":1614969000,"product":"LIRAGLUTIDE (QTY: 25 GRMS\/ USD 900 PER GRMS)","address":"7-1-27, AMEERPET","city":"HYDERABAD, ANDHRA PRADESH","supplier":"SINOPEP ALLSINO BIOPHARMACEUTICAL ","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"0.025","unit":"KGS","unitRateFc":"900000","totalValueFC":"22839.5","currency":"USD","unitRateINR":"66510000","date":"06-Mar-2021","totalValueINR":"1662750","totalValueInUsd":"22839.5","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3045495","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"","customerAddress":"7-1-27, AMEERPET"},{"dataSource":"API Import","activeIngredients":"LIRAGLUTIDE","year":"2021","qtr":"Q1","strtotime":1616437800,"product":"LIRAGLUTIDE SODIUM SALT (TEST LIC.NO. TL\/AZ\/17\/003164) FOR R& D PURPOSE NOT FOR SALE","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGARHIGHWAY SATELLITE CROSS ROADS,","city":"AHMEDABAD\/GUJRAT","supplier":"SINOPEP ALL SINO ","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"ZYDUS LIFESCIENCES","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"750","totalValueFC":"17273","currency":"USD","unitRateINR":"62875","date":"23-Mar-2021","totalValueINR":"1257500","totalValueInUsd":"17273","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"3268226","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGARHIGHWAY SATELLITE CROSS ROADS,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1623695400,"product":"LIRAGLUTIDE (FOR TESTING PURPOSE ONLY) (2 PACKS 20G + 10G)","address":"159, C.S.T. ROAD,KALINA, SANTACRUZ (E)","city":"MUMBAI,MAHARASHTRA","supplier":"HYBIO PHARMACEUTICAL (WUHAN) CO., LTD","supplierCountry":"CHINA","foreign_port":"GUANGZHOU","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"30","unit":"GMS","unitRateFc":"1800","totalValueFC":"57313.4","currency":"USD","unitRateINR":"140505","date":"15-Jun-2021","totalValueINR":"4215150","totalValueInUsd":"57313.4","indian_port":"BOMBAY AIR","hs_no":"29371900","bill_no":"4321148","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"GUANGZHOU","supplierAddress":"","customerAddress":"159, C.S.T. ROAD,KALINA, SANTACRUZ (E)"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629311400,"product":"LIRAGLUTIDE","address":"L\/204, MANTRI WOODLANDS, B.G. ROAD, BANGALORE","city":"KARNATAKA STATE","supplier":"MERIDIAN INDUSTRIES (ASIA PACIFIC) PTE LTD","supplierCountry":"SINGAPORE","foreign_port":"SINGAPORE","customer":"TENSHI KAIZEN PRIVATE ","customerCountry":"INDIA","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"850","totalValueFC":"173858.8","currency":"USD","unitRateINR":"64473.4","date":"19-Aug-2021","totalValueINR":"12894670","totalValueInUsd":"173858.8","indian_port":"BANGALORE AIR","hs_no":"29379090","bill_no":"5115795","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"SINGAPORE","selfForZScoreResived":"Pharma Grade","supplierPort":"SINGAPORE","supplierAddress":"","customerAddress":"L\/204, MANTRI WOODLANDS, B.G. ROAD, BANGALORE"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1635186600,"product":"LIRAGLUTIDE [DRUG LICENCE NO: TL\/HZ\/21\/003609 DT: 17.08.2021]","address":"18\/1&3,AZAMABAD","city":"HYDERABAD,TELANGANA","supplier":"HYBIO PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"NA","customer":"BIOLOGICAL E","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"2000","totalValueFC":"5059.3","currency":"USD","unitRateINR":"379000","date":"26-Oct-2021","totalValueINR":"379000","totalValueInUsd":"5059.3","indian_port":"HYDERABAD AIR","hs_no":"29372900","bill_no":"6001520","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"18\/1&3,AZAMABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637778600,"product":"LIRAGLUTIDE","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"HYBIO PHARMACEUTICAL (WUHAN) CO., LTD.","supplierCountry":"CHINA","foreign_port":"GUANGZHOU","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.90","actualQuantity":"900","unit":"GMS","unitRateFc":"1200","totalValueFC":"1089118.2","currency":"USD","unitRateINR":"90120","date":"25-Nov-2021","totalValueINR":"81108000","totalValueInUsd":"1089118.2","indian_port":"M\/s MAHARASHTRA AIRPORT DEVELOPMENTCOMPANYLIMITED","hs_no":"29371900","bill_no":"1001570","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"GUANGZHOU","supplierAddress":"N\/A","customerAddress":"159, C.S.T. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1638469800,"product":"LIRAGLUTIDE (QTY : 15 GRM) (TL LIC : TL\/AZ\/21\/00072) FOR R&DPURPOSE NOT FOR SALE","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"MERIDIAN INDUSTRIES (ASIA PACIFIC) PTE LTD","supplierCountry":"CHINA","foreign_port":"N\/A","customer":"ZYDUS LIFESCIENCES","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"15","unit":"GMS","unitRateFc":"865","totalValueFC":"14767.2","currency":"USD","unitRateINR":"74255.5","date":"03-Dec-2021","totalValueINR":"1113832.5","totalValueInUsd":"14767.2","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"6522520","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641580200,"product":"LIRAGLUTIDE (TL LIC : TL\/AZ\/21\/000772) QTY. 10 GRM) FOR R&DPURPOSE NOT FOR SALE","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"MERIDIAN INDUSTRIES (ASIA PACIFIC) PTE LTD","supplierCountry":"CHINA","foreign_port":"#N\/A","customer":"ZYDUS LIFESCIENCES","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"865","totalValueFC":"10476","currency":"USD","unitRateINR":"78039","date":"08-Jan-2022","totalValueINR":"780390","totalValueInUsd":"10476","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"7002550","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649010600,"product":"FOCLIRAGLUTIDE API 3G - LOT#0342103A (QTY 3 G)","address":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,","city":"HYDERABAD,TELANGANA","supplier":"VIATRIS","supplierCountry":"IRELAND","foreign_port":"NA","customer":"VIATRIS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.003","unit":"KGS","unitRateFc":"1308600","totalValueFC":"4446.2","currency":"EUR","unitRateINR":"111819870","date":"04-Apr-2022","totalValueINR":"335459.61","totalValueInUsd":"4446.2","indian_port":"BANGALORE AIR","hs_no":"29371900","bill_no":"8134446","productDescription":"API","marketType":"REGULATED MARKET","country":"IRELAND","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671474600,"product":"LIRAGLUTIDE (BATCH NO: 10131190501)(QTY:20GMS, VALUE:USD 12600)(7GM X 1 BAG,13GM X 1 BAG)(AS PER INVOICE)","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"SINOPEP ALLSINO BIOPHARMACEUTICAL ","supplierCountry":"CHINA","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"630000","totalValueFC":"13032.3","currency":"USD","unitRateINR":"53697283.5","date":"20-Dec-2022","totalValueINR":"1073945.67","totalValueInUsd":"13032.3","indian_port":"HYDERABAD AIR","hs_no":"29371900","bill_no":"3830563","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671820200,"product":"LIRAGLUTIDE (QTY: 300 GMS, VALUE: USD 294000)","address":"5-5-35\/102&103,PLOT NO 22,23,SY NO ,379,380,381,PRASHANTH NAGAR,KP","city":"HYDERABAD,TELANGANA","supplier":"BACHEM AG","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"EXTROVIS AG","customerCountry":"INDIA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"980000","totalValueFC":"300818","currency":"USD","unitRateINR":"82630950","date":"24-Dec-2022","totalValueINR":"24789285","totalValueInUsd":"300818","indian_port":"HYDERABAD AIR","hs_no":"29371900","bill_no":"3902695","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"5-5-35\/102&103,PLOT NO 22,23,SY NO ,379,380,381,PRASHANTH NAGAR,KP"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675276200,"product":"LIRAGLUTIDE","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"SINOPEP- ALLSINO BIOPHARMACEUTICAL CO., LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"2.88","actualQuantity":"2.88","unit":"KGS","unitRateFc":"630000","totalValueFC":"1835489.5","currency":"USD","unitRateINR":"52636500","date":"02-Feb-2023","totalValueINR":"151593120","totalValueInUsd":"1835489.5","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"4466868","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676399400,"product":"LIRAGLUTIDE (TEST LIC: TL\/AZ\/21\/000772) FOR R&D PURPOSE NOTFOR SALE","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"SINOPEP ALL SINO ","supplierCountry":"CHINA","foreign_port":"NA","customer":"ZYDUS LIFESCIENCES LIMITED","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"750","totalValueFC":"9217.8","currency":"USD","unitRateINR":"76130","date":"15-Feb-2023","totalValueINR":"761300","totalValueInUsd":"9217.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"4656109","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677436200,"product":"LIRAGLUTIDE","address":"PLOT NO 2A & 2B, BIOTECH PARK,,PHA SE II, LALGADI MALAKPET,","city":"HYDERABAD,TELANGANA","supplier":"M\/S SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"CHEMO","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"1000","totalValueFC":"20256.7","currency":"USD","unitRateINR":"83650","date":"27-Feb-2023","totalValueINR":"1673000","totalValueInUsd":"20256.7","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"4824737","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO 2A & 2B, BIOTECH PARK,,PHA SE II, LALGADI MALAKPET,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692037800,"product":"LIRAGLUTIDE","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,, ROAD NO.3, BANJARA HILLS,","city":"HYDERABAD","supplier":"SINOPEPALLSINO BIOPHARMACETIC","supplierCountry":"CHINA","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"630000","totalValueFC":"778073.5","currency":"USD","unitRateINR":"53173509.9","date":"15-Aug-2023","totalValueINR":"64452739.21","totalValueInUsd":"778073.5","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,, ROAD NO.3, BANJARA HILLS,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697394600,"product":"LIRAGLUTIDE","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"HYBIO PHARMACEUTICAL (WUHAN) CO LTD","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"15","unit":"GMS","unitRateFc":"1000","totalValueFC":"17405.7","currency":"USD","unitRateINR":"96577.4","date":"16-Oct-2023","totalValueINR":"1448660.85","totalValueInUsd":"17405.7","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"8317848","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"NO.9 LINKONG WEST STREET, HENGDIANSTREET,HUANGPI DISTRICT, WUHAN CITYHUBEI PROVINCE CHINA Wuhan, , Chin China","customerAddress":"159, C.S.T. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699036200,"product":"LIRAGLUTIDE (QTY: 300 GMS)","address":"FLAT NO 7536 2ND WING 7TH BLOCK,JA","city":"HYDERABAD,TELANGANA","supplier":"BACHEM AG","supplierCountry":"UNITED STATES","foreign_port":"LOS ANGELES","customer":"EXTROVIS AG","customerCountry":"INDIA","quantity":"0.30","actualQuantity":"300","unit":"GMS","unitRateFc":"1072.2","totalValueFC":"325052.8","currency":"USD","unitRateINR":"90224.8","date":"04-Nov-2023","totalValueINR":"27067436.55","totalValueInUsd":"325052.8","indian_port":"Hyderabad Air","hs_no":"29371900","bill_no":"8626809","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"LOS ANGELES","supplierAddress":"1271 AVENIDA CHELSEAVISTA 92081USA US","customerAddress":"FLAT NO 7536 2ND WING 7TH BLOCK,JA"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699468200,"product":"LIRAGLUTIDE (PPL1190) (5G)","address":"H NO.141, SILPA BRINDAVAN,","city":"KUKATPALLY, HYDERABAD, AP.","supplier":"POLYPEPTIDE GROUP","supplierCountry":"UNITED STATES","foreign_port":"LOS ANGELES","customer":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES ","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"0.005","unit":"KGS","unitRateFc":"1600000","totalValueFC":"8084.5","currency":"USD","unitRateINR":"134640000","date":"09-Nov-2023","totalValueINR":"673200","totalValueInUsd":"8084.5","indian_port":"Hyderabad Air","hs_no":"29371900","bill_no":"8705352","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"LOS ANGELES","supplierAddress":"365 Maple Avenue Torrance, CA 90503USA United StatesSDNF United States","customerAddress":"H NO.141, SILPA BRINDAVAN,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707762600,"product":"LIRAGLUTIDE (QTY:3 GRAMS)ASPER INV","address":"PLOT NO.2, MAITRIVIHAR,","city":"HYDERABAD\/ANDHRA PRADESH","supplier":"HYBIO PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"GUANGZHOU","customer":"AUROBINDO PHARMA LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.003","unit":"KGS","unitRateFc":"1350000","totalValueFC":"7414.3","currency":"USD","unitRateINR":"205063616.7","date":"13-Feb-2024","totalValueINR":"615190.85","totalValueInUsd":"7414.3","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"2116322","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"GUANGZHOU","supplierAddress":"HYBIO INNOVATION INDUSTRY BUILDINGNO.7 GUANSHENG 4TH RD GUANLAN HIGH-TECH PARK LONGHUA DISTRICT SHENZHEN China","customerAddress":"PLOT NO.2, MAITRIVIHAR,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717093800,"product":"LIRAGLUTIDE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"PHARMATECH","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"SYNGENE INTERNATIONAL LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"416","totalValueFC":"421","currency":"USD","unitRateINR":"35090","date":"31-May-2024","totalValueINR":"35090","totalValueInUsd":"421","indian_port":"Biocon-SEZ","hs_no":"29420090","bill_no":"1006756","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"N\/A","customerAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725301800,"product":"LIRAGLUTIDE","address":"H NO.141, SILPA BRINDAVAN,","city":"KUKATPALLY, HYDERABAD, AP.","supplier":"SINOPEP ALLSINO BIOPHARMACEUTICAL ","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES ","customerCountry":"INDIA","quantity":"1.27","actualQuantity":"1268.53","unit":"GMS","unitRateFc":"275","totalValueFC":"353211.6","currency":"USD","unitRateINR":"23333.8","date":"03-Sep-2024","totalValueINR":"29599561.89","totalValueInUsd":"353211.6","indian_port":"Hyderabad Air","hs_no":"29379090","bill_no":"5400877","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO 28, LINPU ROAD,ECONOMIC&TECHNOLO GICAL DEVELOPMENT ZONE,LIANYUNGANG, JIANGSU PROVINCE,CHINA China","customerAddress":"H NO.141, SILPA BRINDAVAN,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725301800,"product":"LIRAGLUTIDE","address":"H NO.141, SILPA BRINDAVAN,","city":"KUKATPALLY, HYDERABAD, AP.","supplier":"SINOPEP ALLSINO BIOPHARMACEUTICAL ","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES ","customerCountry":"INDIA","quantity":"1.86","actualQuantity":"1859.9","unit":"GMS","unitRateFc":"275","totalValueFC":"517873.6","currency":"USD","unitRateINR":"23333.8","date":"03-Sep-2024","totalValueINR":"43398441.63","totalValueInUsd":"517873.6","indian_port":"Hyderabad Air","hs_no":"29379090","bill_no":"5400877","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO 28, LINPU ROAD,ECONOMIC&TECHNOLO GICAL DEVELOPMENT ZONE,LIANYUNGANG, JIANGSU PROVINCE,CHINA China","customerAddress":"H NO.141, SILPA BRINDAVAN,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1727721000,"product":"LIRAGLUTIDE WS","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"HYBIO PHARMACEUTICAL (WUHAN) CO., LTD.","supplierCountry":"CHINA","foreign_port":"GUANGZHOU BAIYUN INTERNATIONAL APT, 44","customer":"LUPIN LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"21754","totalValueFC":"21902.5","currency":"USD","unitRateINR":"1840389","date":"01-Oct-2024","totalValueINR":"1840389","totalValueInUsd":"21902.5","indian_port":"M\/s MAHARASHTRA AIRPORT DEVELOPMENTCOMPANYLIMITED","hs_no":"29371900","bill_no":"1002418","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"GUANGZHOU BAIYUN INTERNATIONAL APT, 44","supplierAddress":"N\/A","customerAddress":"159, C.S.T. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732732200,"product":"LIRAGLUTIDE","address":"H NO.141, SILPA BRINDAVAN,","city":"KUKATPALLY, HYDERABAD, AP.","supplier":"SINOPEP ALLSINO BIOPHARMACEUTICAL ","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"ORBICULAR PHARMACEUTICAL TECHNOLOGIES ","customerCountry":"INDIA","quantity":"0.37","actualQuantity":"370.69","unit":"GMS","unitRateFc":"275","totalValueFC":"103101.6","currency":"USD","unitRateINR":"23471.3","date":"28-Nov-2024","totalValueINR":"8700557.66","totalValueInUsd":"103101.6","indian_port":"Hyderabad Air","hs_no":"29371900","bill_no":"6926903","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"NO 28, LINPU ROAD,ECONOMIC&TECHNOLO GICAL DEVELOPMENT ZONE,LIANYUNGANG, JIANGSU PROVINCE,CHINA China China","customerAddress":"H NO.141, SILPA BRINDAVAN,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733769000,"product":"LIRAGLUTIDE (QTY:1500GMS, VALUE:USD 412500) LIRAGLUTIDE","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"SINOPEP- ALLSINO BIOPHARMACEUTICAL CO., LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"1.50","actualQuantity":"1500","unit":"GMS","unitRateFc":"280.5","totalValueFC":"424122.2","currency":"USD","unitRateINR":"24024.8","date":"10-Dec-2024","totalValueINR":"36037237.5","totalValueInUsd":"424122.2","indian_port":"Hyderabad Air","hs_no":"29371900","bill_no":"7149995","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.28 LINPU ROAD, ECONOMIC & TECHNO LOGICAL DEVELOPMENT ZONE, LIANYUNGA NG , JIANGSU PROVINCE, CHINA China","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"LIRAGLUTIDE (QTY:5921.60 GMS, VALUE:USD 1628440) LIRAGLUTIDE","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"SINOPEP- ALLSINO BIOPHARMACEUTICAL CO., LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"5.92","actualQuantity":"5.9216","unit":"KGS","unitRateFc":"275000","totalValueFC":"1680186.1","currency":"USD","unitRateINR":"24108975","date":"24-Dec-2024","totalValueINR":"142763706.4","totalValueInUsd":"1680186.1","indian_port":"Hyderabad Air","hs_no":"29371900","bill_no":"7432100","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.28 LINPU ROAD, ECONOMIC & TECHNO LOGICAL DEVELOPMENT ZONE, LIANYUNGA NG , JIANGSU PROVINCE, CHINA China","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

01

Novo Nordisk (Pty) Ltd

Denmark

Biotech Showcase

Not Confirmed

02

Novo Nordisk (Pty) Ltd

Denmark

Biotech Showcase

Not Confirmed

03

Novo Nordisk (Pty) Ltd

Denmark

Biotech Showcase

Not Confirmed

04

Novo Nordisk (Pty) Ltd

Denmark

Biotech Showcase

Not Confirmed

05

Novo Nordisk (Pty) Ltd

Denmark

Biotech Showcase

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

Topical

Film Formers & Plasticizers

Solubilizers

Emulsifying Agents

Controlled & Modified Release

Thickeners and Stabilizers

Coating Systems & Additives

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

01

Brand Name : Xultophy

Denmark

BIO Partnering at JPM

Not Confirmed

02

Brand Name : Saxenda

Denmark

BIO Partnering at JPM

Not Confirmed

03

Brand Name : Saxenda

Denmark

BIO Partnering at JPM

Not Confirmed

04

Brand Name : Victoza

Denmark

BIO Partnering at JPM

Not Confirmed

05

Brand Name : Victoza

Denmark

BIO Partnering at JPM

Not Confirmed

06

Brand Name : Victoza

Denmark

BIO Partnering at JPM

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

01

NOVO

BIO Partnering at JPM

Not Confirmed

02

NOVO

BIO Partnering at JPM

Not Confirmed

03

NOVO

BIO Partnering at JPM

Not Confirmed

04

NOVO NORDISK INC

BIO Partnering at JPM

Not Confirmed

05

NOVO

BIO Partnering at JPM

Not Confirmed

06

NOVO

BIO Partnering at JPM

Not Confirmed

07

NOVO

BIO Partnering at JPM

Not Confirmed

08

NOVO

BIO Partnering at JPM

Not Confirmed

09

NOVO NORDISK INC

BIO Partnering at JPM

Not Confirmed

10

NOVO

BIO Partnering at JPM

Not Confirmed

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Health Canada Patents

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Others

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Liraglutide Manufacturers

A Liraglutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liraglutide, including repackagers and relabelers. The FDA regulates Liraglutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liraglutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Liraglutide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Liraglutide Suppliers

A Liraglutide supplier is an individual or a company that provides Liraglutide active pharmaceutical ingredient (API) or Liraglutide finished formulations upon request. The Liraglutide suppliers may include Liraglutide API manufacturers, exporters, distributors and traders.

click here to find a list of Liraglutide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Liraglutide USDMF

A Liraglutide DMF (Drug Master File) is a document detailing the whole manufacturing process of Liraglutide active pharmaceutical ingredient (API) in detail. Different forms of Liraglutide DMFs exist exist since differing nations have different regulations, such as Liraglutide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Liraglutide DMF submitted to regulatory agencies in the US is known as a USDMF. Liraglutide USDMF includes data on Liraglutide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Liraglutide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Liraglutide suppliers with USDMF on PharmaCompass.

Liraglutide KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Liraglutide Drug Master File in Korea (Liraglutide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Liraglutide. The MFDS reviews the Liraglutide KDMF as part of the drug registration process and uses the information provided in the Liraglutide KDMF to evaluate the safety and efficacy of the drug.

After submitting a Liraglutide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Liraglutide API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Liraglutide suppliers with KDMF on PharmaCompass.

Liraglutide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Liraglutide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Liraglutide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Liraglutide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Liraglutide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Liraglutide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Liraglutide suppliers with NDC on PharmaCompass.

Liraglutide GMP

Liraglutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Liraglutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Liraglutide GMP manufacturer or Liraglutide GMP API supplier for your needs.

Liraglutide CoA

A Liraglutide CoA (Certificate of Analysis) is a formal document that attests to Liraglutide's compliance with Liraglutide specifications and serves as a tool for batch-level quality control.

Liraglutide CoA mostly includes findings from lab analyses of a specific batch. For each Liraglutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Liraglutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Liraglutide EP), Liraglutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Liraglutide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Menu

Post Enquiry

Market Place

Search